Regulatory context
Regulatory context; not efficacy evidence
No matched treatment-outcome population.
Reported findings. No benefit claim from this context reference.
Nonresponse. Not reported in reviewed excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Context citations do not fill outcome-evidence gaps.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Human trial
AOD9604 human trial safety synthesis · Journal of Endocrinology and Metabolism 2013
893 adults across six trials; mostly otherwise healthy adults with obesity, 2001–2006.
Reported findings. Authors described tolerability broadly comparable with placebo; generally no significant between-group IGF-1 or glucose-tolerance changes; no detected antibodies in selected samples.
Nonresponse. Weight-loss efficacy was not established by this safety synthesis.
Harms. Headache, gastrointestinal events and euphoria occurred. Severe chest tightness during IV treatment and serious diarrhea in an oral study were considered possibly related; an isolated glucose increase was also reported. These body findings conflict with the abstract’s blanket no-related-serious-event summary.
Limits. Longer studies were oral, up to 24 weeks. Findings do not establish subcutaneous or commercial-product safety. Sponsor-linked summary, selected antibody testing and inconsistent adverse-event wording limit interpretation.
Preparation: Controlled AOD9604 study material; oral capsules/tablets and intravenous preparation, not commercial-vial equivalence. Route: oral and short-term intravenous; no subcutaneous cohort
Read original source ↗Editorial review 2026-10-09. Clinician review pending.